Physician profile
Joanna Morris
NPI 1821169145
$3,003.19
in general payments reported to CMS, 2019-2025
29 companies · $533 in 2025
The $533 reported for 2025 was more than what 94% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $244 · 2020: $133 · 2021: $309 · 2022: $358 · 2023: $638 · 2024: $787 · 2025: $533.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,958.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,958.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $557.29 | 2019-2025 | Dyanavel Xr, Quillichew Er, Quillivant |
| Corium, LLC | $418.92 | 2021-2025 | Azstarys |
| Supernus Pharmaceuticals, INC. | $320.76 | 2021-2025 | Qelbree, Qelbree |
| Ironshore Pharmaceuticals INC. | $293.61 | 2019-2024 | Jornay Pm |
| Cranial Technologies, INC | $196.96 | 2019-2025 | Doc Band |
| Sanofi Pasteur INC. | $168.11 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $160.91 | 2024-2025 | |
| Neos Therapeutics, LP | $120.77 | 2021-2023 | Adzenys Xr-Odt |
| Takeda Pharmaceuticals U.S.A., INC. | $118.31 | 2020-2021 | |
| Sobi, INC | $80.38 | 2020-2023 | |
| Glaxosmithkline, LLC. | $65.30 | 2019-2025 | Penmenvy |
| Adlon Therapeutics L.P. | $56.75 | 2020-2021 | |
| Collegium Pharmaceutical, INC. | $49.13 | 2025 | Jornay Pm |
| Pfizer INC. | $44.39 | 2023 | |
| Merck Sharp & Dohme LLC | $44.08 | 2022-2024 | Vaxneuvance, Vaxelis, Gardasil 9 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alk-Abello, INC | $33.47 | 2025 | Neffy, Odactra, Grastek |
| Kaleo, INC. | $29.54 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $26.33 | 2024 | Flumist Quadrivalent |
| Siemens Medical Solutions USA, INC. | $23.18 | 2024 | Acuson Origin Diagnostic Ultrasound System |
| Arbor Pharmaceuticals, INC. | $22.77 | 2019 | |
| Biogen, INC. | $21.80 | 2024 | Skyclarys |
| Genentech USA, INC. | $21.53 | 2019 | |
| Biomerieux INC | $21.00 | 2025 | |
| Ultragenyx Pharmaceutical INC. | $20.42 | 2022 | |
| Seqirus USA INC | $19.59 | 2021 | |
| Noven Therapeutics, LLC | $18.67 | 2023 | Xelstrym |
| Abbvie INC. | $17.66 | 2021 | |
| Allegis Pharmaceuticals, LLC | $17.28 | 2023 | Spinosad |
| Vertical Pharmaceuticals, LLC | $14.28 | 2024 | Relexxii |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joanna Morris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.